What question did this study set out to answer?

The study aims to develop a nano-prodrug that increases oxidative stress to exploit redox vulnerabilities in melanoma treatment.

Cascade-activatable nano-prodrug amplifies ROS-RNS signaling to target NQO1-associated redox vulnerability for melanoma therapy

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial reveals redox-amplifying nano-prodrug enhances ferroptosis in melanoma, indicating promising therapeutic strategy.

The study aims to develop a nano-prodrug that increases oxidative stress to exploit redox vulnerabilities in melanoma treatment.
Constructed a glutathione-responsive nanoplatform (HFSAL) using a disulfide-bridged scaffold and a co-loaded drug.
Conducted transcriptomic analyses to evaluate NQO1 expression in melanoma and its association with oxidative stress.
Assessed tumor growth inhibition and metastasis suppression in vivo.
The HFSAL nano-prodrug significantly inhibited tumor growth and metastasis, demonstrating a substantial effect on treatment outcomes.
Induced synergistic ferroptosis and apoptosis in tumor cells, enhancing therapeutic efficacy.
Achieved favorable biosafety profiles in the tested models.

Tang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark